1887

Abstract

SUMMARY

The priming activities of human IFN-α, IFN-β and IFN-γ were compared on the same antiviral basis using human buffy coat leukocytes stimulated with Sendai virus or concanavalin A (Con A) to produce IFN-α or IFN-γ, respectively. Pretreatment of leukocytes with any type of IFN enhanced their IFN-α and IFN-γ production, but IFN-α and IFN-β had more potent priming activities than IFN-γ. IFN-α and IFN-γ did not potentiate the priming activity of each other in either the IFN-α- or the IFN-γ-producing system. Pretreatment of leukocytes with relatively high doses of IFN-α or IFN-β (1000 to 3000 IU/ml) resulted in a 40- to 50-fold increase in the IFN-γ production of Con A-stimulated leukocytes. This observation will be of use in producing IFN-γ with a high titre.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-66-4-893
1985-04-01
2021-10-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/66/4/JV0660040893.html?itemId=/content/journal/jgv/10.1099/0022-1317-66-4-893&mimeType=html&fmt=ahah

References

  1. Béládi I., Tóth M., Mécs I., Tóth S., Taródi B., Pusztai R., Koltai M. 1980; Production and purification of human leukocyte interferon. In Proceedings of the International Conference on Clinical Potentials of Interjeron in Viral Diseases and Malignant Tumors pp 31–37 Edited by Kono R., Vilcek J. Japan Medical Research Foundation, Publication No. 15;
    [Google Scholar]
  2. Blalock J. E., Georgiades J. A., Langford M. P., Johnson H. M. 1980; Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cellular Immunology 49:390–394
    [Google Scholar]
  3. Burke D. C. 1981/82; Biological properties of virus-induced interferons. Texas Reports on Biology and Medicine 41:13–18
    [Google Scholar]
  4. Cantell K., Hirvoven S., Mogensen K. E., Pyhala L. 1974; Human leukocyte interferon: production, purification, stability and animal experiments. In The Production and Use of Interferon for the Treatment and Prevention of Human Virus Infections, In Vitro Monograph No. 3 pp 35–38 Edited by Waymouth C. Rockville: Tissue Culture Association;
    [Google Scholar]
  5. Dolei A., Capobianchi M. R., Ameglio F. 1983; Human interferon-y enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-α and interferon-β. Infection and Immunity 40:172–176
    [Google Scholar]
  6. Fleischmann W. R., Georgiades J. A., Osborne L. C., Johnson H. M. 1979; Potentiation of interferon activity by mixed preparation of fibroblast and immune interferon. Infection and Immunity 26:248–253
    [Google Scholar]
  7. Fleischmann W. R., Klein K. M., Baron S. 1980; Potentiation of antitumor effect of virus-induced interferon by mouse interferon preparations. Journal oj the National Cancer Institute 65:963–966
    [Google Scholar]
  8. Langford M. P., Georgiades J. A., Stanton G. J., Dianzani F., Johnson H. M. 1979; Large-Scale production and physicochemical characterization of human immune interferon. Infection and Immunity 26:36–41
    [Google Scholar]
  9. Rubin B. Y., Gupta S. L. 1980; Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proceedings of the National Academy of Sciences, U,. S,. A 77:5928–5932
    [Google Scholar]
  10. Stewart W. E. II, Gosser L. B., Lockart R. Z. 1971; Priming: a new-antiviral function of interferon. Journal of Virology 7:792–801
    [Google Scholar]
  11. Stewart W. E. II, De Clercq E., Billiau A., Desmyter J., De Somer P. 1972; Increased susceptibility of cells treated with interferon to the toxicity of poly-riboinosinic poly-ribocytidylic acid. Proceedings of the National Academy of Sciences, U,. S,. A 69:1851–1854
    [Google Scholar]
  12. Stewart W. E. II, Blalock J. E., Burke D. C., Chany C., Dunnick J. K., Falcoff E., Friedman R. M., Galasso G. J., Joklik W. K., Vilcek J. T., Youngner J. S., Zoon K. C. 1980; Interferon nomenclature. European Journal oj Immunology 10:660
    [Google Scholar]
  13. Van Damme J., Billiau A., De Ley M., De Somer P. 1983; An interferon-β-like or interferon-inducing protein released by mitogen-stimulated human leukocytes. Journal of General Virology 64:1819–1822
    [Google Scholar]
  14. Weigent D. A., Langford M. P., Fleischmann W. R., Stanton G. J. 1983; Potentiation of lymphocyte natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon. Infection and Immunity 40:35–38
    [Google Scholar]
  15. Weil J. J., Epstein C. J., Epstein L. B., Sedmak J. J., Sabran J. L., Grossberg S. E. 1983; A unique Set of polypeptides is induced by y interferon in addition to those induced in common with α and β interferons. Nature, London 301:437–439
    [Google Scholar]
  16. Wiranowska-Stewart M., Lin L. S., Braude I. A., Stewart W. E. II 1980; Production, partial purification and characterization of human and mouse interferon type II. Molecular Immunology 17:625–633
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-66-4-893
Loading
/content/journal/jgv/10.1099/0022-1317-66-4-893
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error